2, Sep 2026
FAGE ANNOUNCES MULTI-YEAR PARTNERSHIP WITH THE FIA WORLD ENDURANCE CHAMPIONSHIP LONE STAR LE MANS RACE
FAGE brings its history of culinary excellence to the world-renowned FIA WEC circuit
STRASSEN, Luxembourg, Sept. 2, 2026 /PRNewswire/ — FAGE International S.A. (the “Company” or “FAGE”), a leading international Greek yogurt company, today announced a new multi-year partnership with the FIA WEC Lone Star Le Mans race, becoming an Official Partner of the premier endurance racing event and strengthening its ties to global motorsports.
Through the multi-year agreement, FAGE will bring its signature range of Greek yogurt to the growing WEC fanbase through direct touchpoints including exclusive culinary experiences from the Le Mans Spirit Club to the paddock, offering fans elevated tastes throughout the race weekend.
“Our partnership with FIA WEC Lone Star Le Mans brings together two organizations with a deep respect for heritage, craftsmanship and performance,” said Athanassios Filippou, FAGE’s CEO. “We’re excited to give WEC’s passionate community tastes they’ll remember, and share in the championship’s ambition to continually challenge expectations.”
Celebrated for its time-honored culinary craftsmanship and dedication to taste and quality, FAGE’s presence at FIA WEC Lone Star Le Mans unites the two organizations’ unwavering commitment to performance and excellence.
Marius Louvet, Marketing and Communication Director, FIA World Endurance Championship, said:
“We are delighted to welcome FAGE on-board as a partner for Lone Star Le Mans. FAGE is a well-established and extremely successful international consumer brand, and this partnership clearly demonstrates FIA WEC’s ability to attract interest from beyond the traditional motorsport and automotive ecosystem.
“FAGE will have a highly visible and tangible presence over the race weekend at COTA, featuring multiple activations that underscore our commitment to continuing to enrich the fan experience and bring new brands closer to the championship’s ever-growing audience. It will be a pleasure to host the FAGE team on-site.”
Featuring cutting-edge, purpose-built racing prototypes piloted by professional drivers in the headlining Hypercar category, alongside production-based sportscars comprising a blend of professionals and amateurs in LMGT3, FIA WEC pits the world’s leading competitors against each other in a sensational spectacle of sporting prowess realized through a test of speed, strategy, engineering and human performance.
As an Official Partner, FAGE will be visible across Lone Star Le Mans, supported by on-site activations and digital content for fans to engage with, joining a global celebration of endurance racing while bringing its own heritage and culinary expertise to one of the world championship’s most distinctive events.
About FAGE
FAGE is a leading dairy company passionate about sharing the finest dairy products with food lovers around the globe. Founded in Greece in 1926, FAGE has grown from its Greek roots into an international brand, offering exceptional dairy products in over 30 countries. Best known for its signature Greek strained yogurt, FAGE continues to inspire healthy lifestyles and deliver deliciously crafted products.
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/fage-announces-multi-year-partnership-with-the-fia-world-endurance-championship-lone-star-le-mans-race-302867067.html
- 0
- By Sai Krishna
2, Sep 2026
Futura MedTech Appoints Abhishek Bhargava as Group CEO
BENGALURU, India, Sept. 2, 2026 /PRNewswire/ — Futura MedTech today announced the appointment of Abhishek Bhargava as Group Chief Executive Officer (CEO), marking an important milestone in the company’s journey as it enters its next phase of growth and transformation.
With nearly two decades of experience across leading global healthcare and MedTech organisations, Abhishek brings extensive expertise in building and scaling complex, multi-therapy MedTech businesses.
Most recently, Abhishek was a member of Medtronic India’s Leadership Team, where he served as Senior Director, Transformation & Growth Business. During his nine-year tenure with Medtronic India, he led multiple operating units and business portfolios, including Surgical Innovations covering Sutures, Stapling, Energy, Hernia and Visualization. His leadership experience also spans Coronary & Renal Denervation, Structural Heart, Acute Care & Monitoring, Endoscopy, Surgical Robotics, Cardiac Rhythm Management and Cardiac Ablation Solutions.
Earlier in his career, Abhishek held progressive leadership roles at Johnson & Johnson MedTech across the Cordis and Biosense Webster franchises, where he contributed to growth in interventional cardiology and electrophysiology.
Beyond his corporate leadership experience, Abhishek brings an entrepreneurial perspective to his new role. He co-founded SmartMedicalBuyer.com, one of India’s early digital platforms focused on medical supply procurement.
An alumnus of XLRI Jamshedpur and Hindu College, University of Delhi, Abhishek combines strategic business expertise with hands-on leadership experience across diverse healthcare technologies and markets.
His appointment reinforces Futura MedTech’s commitment to building a diversified and professionally managed MedTech platform. With a strong foundation, trusted brand and passionate teams, the company is focused on accelerating its growth and strengthening its position within India’s healthcare and medical technology ecosystem.
As Group CEO, Abhishek will lead Futura MedTech into its next chapter, driving the organisation’s strategic growth and supporting its ambition to build one of India’s leading diversified MedTech platforms.
About Futura MedTech
Futura MedTech is focused on building a diversified and professionally managed MedTech platform, supported by a strong foundation, trusted brands and a commitment to advancing healthcare through innovation and growth.
Media Contact
Futura Surgicare Pvt. Ltd.
hello@futuramedtech.com
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/futura-medtech-appoints-abhishek-bhargava-as-group-ceo-302867642.html
2, Sep 2026
Why AI Needs More Than Models: Inside CLOE’s Human Perception Architecture
New details reveal how Iyuno’s CLOE combines sensory inputs, cognitive integration, and persistent memory to create a cohesive understanding of content.
BURBANK, Calif., Sept. 2, 2026 /PRNewswire/ — Following the introduction of CLOE’s multi-agent architecture, Iyuno today shared new details on the human-inspired system that enables the platform to build a persistent, reusable understanding of content.
Rather than processing content as isolated inputs, CLOE was designed to mirror how people naturally experience stories—combining what they see, hear, and read before connecting those signals through memory, reasoning, and context into a cohesive understanding.
“People don’t understand a story through dialogue alone or visuals alone,” said David Lee, CEO of Iyuno. “We naturally combine multiple sensory inputs, connect them with memory and reasoning, and build understanding over time. CLOE was designed to follow that same process.”
At the foundation of the platform is CLOE’s Human Sensory System, where specialized AI agents independently process visual, auditory, and language inputs—including appearance, action, dialogue, tone, music, and subtext.
Those signals are then brought together through Cognitive Integration, where additional agents perform multimodal fusion, reasoning, contextual analysis, and memory formation. Rather than treating each scene as a separate task, CLOE continuously connects relationships, emotional intent, narrative progression, and character continuity into a persistent Context Memory.
The result is a cohesive understanding that extends beyond literal interpretation—capturing the context, relationships, and creative intent that drive storytelling.
“Understanding isn’t created by a single model,” Lee said. “It emerges when multiple perspectives are brought together into a shared contextual memory. That’s what allows AI to move beyond processing content to truly understanding it.”
This persistent Context Memory becomes a reusable foundation for future workflows, enabling AI capabilities to operate from the same consistent understanding rather than reconstructing context each time.
Future announcements will explore how this shared contextual foundation powers CLOE Skills across localization, accessibility, creative production, and other content workflows.
About Iyuno
Iyuno (www.iyuno.com) is a global media localization company delivering dubbing, subtitling, and content services for the world’s leading studios, broadcasters, and streaming platforms. With a presence in 45 offices across 29 countries, Iyuno combines creative expertise with innovative technology to help content reach audiences everywhere. The company is also the creator of CLOE, a contextual intelligence platform that transforms content into structured understanding, enabling AI-powered workflows across localization, accessibility, marketing, and emerging content experiences.
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/why-ai-needs-more-than-models-inside-cloes-human-perception-architecture-302866971.html
2, Sep 2026
DECATHLON Strengthens Reach Among Young Families Through Strategic Partnership with FirstCry
~Partnership leverages FirstCry’s 25 million+ registered user base; aims to drive early-stage sports adoption and help children build active, healthy habits for life~
Commenting on the partnership, Sankar Chatterjee, CEO, Decathlon Sports India says “Children today have an incredible array of opportunities to explore new interests and activities. Through this collaboration, Decathlon Sports India and FirstCry aim to support parents in encouraging movement, play and active participation in sports. We believe physical activity is key to holistic wellbeing, fostering not just fitness, but confidence, mental clarity, and social growth. Our goal is to bring high-quality sports gear closer to families, ensuring every child has the tools for all-round development through a convenient and seamless shopping experience.”Commenting on the partnership, Supam Maheshwari, Chief Executive Officer (CEO) & Founder FirstCry, said “At FirstCry, our mission has always been to make parenting simpler by bringing everything a growing child needs under one roof. Our partnership with Decathlon Sports India is a natural extension of that commitment, making high-quality sports gear easily accessible to children and parents across India through the FirstCry platform. By bringing together FirstCry’s deep understanding of young families and nationwide reach with Decathlon’s global sporting expertise, we are making it easier for parents to encourage active, outdoor play and help children build healthy habits from an early age. We are delighted to welcome Decathlon Sports India to the FirstCry platform and look forward to making sports more accessible to the next generation.”
2, Sep 2026
NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury
Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life – Spinal Cord Research Foundation.
SCHLIEREN, Switzerland, Sept. 2, 2026 /PRNewswire/ — NovaGo Therapeutics AG, a clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system, today announced the successful completion of a CHF 24 million (USD 30 million) Series B financing round. The round was led by Neurimmune and Pureos, with participation from existing and new investors. The equity financing is complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.
Proceeds from the financing will be used to advance NovaGo’s lead program into a proof-of-concept (PoC) study in patients with acute spinal cord injury. The study is a fully randomized, double-blind trial enrolling 120 patients across sites in Germany, Spain, and Switzerland.
Spinal cord injury remains an area of high unmet medical need. There are currently no approved regenerative treatment options that restore lost neurological function, leaving patients and their families with limited therapeutic prospects following injury. NovaGo’s approach targets Nogo-A, a protein that inhibits nerve fiber regeneration and neuroplasticity in the central nervous system, with the goal of enabling functional recovery.
“We are excited to see this program progress into this critical stage of clinical testing, bringing us a meaningful step closer to a much-needed treatment for patients living with the consequences of spinal cord injury,” said Prof. Martin Schwab, Chief Scientific Officer of NovaGo Therapeutics.
“Together with NovaGo Therapeutics, we are pioneering a novel approach for the treatment of spinal cord injury using a fully human therapeutic antibody designed to promote nerve outgrowth after injury,” said Prof. Roger M. Nitsch, President and Chief Executive Officer of Neurimmune and a member of the Board of Directors of NovaGo Therapeutics. “We are encouraged by the promising Phase 1 results with NG004 and look forward to advancing the clinical development program together with NovaGo Therapeutics and our co-investors, with generous support from the Swiss Paraplegic Foundation and Wings for Life.”
“We are very pleased to co-lead this financing and support NovaGo’s next stage of development. The progress and results from the Phase 1 study in spinal cord injury are very encouraging and we see great potential to provide a new regenerative treatment option for patients with spinal cord injury,” said Dominik Escher, Managing Partner at Pureos Bioventures.
“We are deeply grateful for the backing of our investors. Support from Wings for Life and the Swiss Paraplegic Foundation have also been instrumental, helping make this crucial development phase possible.” said Stefan Moese, Chief Executive Officer of NovaGo Therapeutics. “Their commitment allows us to move forward with the proof-of-concept study and work toward bringing a much-needed treatment to patients affected by the devastating consequences of spinal cord injury.”
About Pureos Bioventures
Pureos Bioventures is a venture fund advised by the Swiss venture capital firm Pureos Partners. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases. For more information, please visit www.pureosbio.com.
About Neurimmune
Neurimmune is a clinical-stage biopharmaceutical company building next-generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered the anti-ATTR antibody cliramitug (formerly NI006, ALXN2220, Phase 3) for ATTR cardiomyopathy, the anti-misfolded SOD1 antibody AP-101 (Phase 2) for ALS, the anti-Nogo-A antibody NG004 (Phase 1) for spinal cord injury, and the anti-amyloid light chain antibody NI009 (preclinical) for AL amyloidosis.
About NovaGo Therapeutics
NovaGo Therapeutics AG is a clinical-stage biotechnology company developing novel anti-Nogo-A biologics to promote nerve regeneration and functional recovery in patients with diseases and injuries of the central nervous system, including spinal cord injury, stroke, and secondary progressive multiple sclerosis. Founded on pioneering research into Nogo-A as a key inhibitor of neuronal regeneration, NovaGo is advancing its lead candidate through clinical development with the goal of delivering the first regenerative treatment for patients with acute spinal cord injury. NovaGo is based in Switzerland.
For more information, please contact:
NovaGo Therapeutics AG
media@novagotx.com
www.novagotherapeutics.com
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/novago-therapeutics-closes-usd-30-million-series-b-financing-to-advance-proof-of-concept-study-in-acute-spinal-cord-injury-302866193.html
2, Sep 2026
KuCoin Web3 Wallet Advances Onchain Execution with Expanded Swap Routes and Limit Orders
PROVIDENCIALES, Turks and Caicos Islands, Sept. 2, 2026 /PRNewswire/ — KuCoin Web3 Wallet today announced an upgrade to its wallet-native trading infrastructure, bringing intent-based swaps and limit orders into a unified self-custodial interface. Through integrations with UniswapX, PancakeSwapX and 1inch, the update gives users more flexible ways to trade supported crypto assets and tokenized real-world assets directly within the wallet.
Web3 wallets are evolving beyond asset storage into a unified access point for discovering, interacting with, and trading onchain markets. As this shift accelerates, the user experience increasingly depends not only on market access, but also on how efficiently orders are routed and executed. The latest upgrade strengthens this execution layer while reducing the need to navigate multiple DApps and disconnected trading workflows.
Through UniswapX and PancakeSwapX, eligible swaps can access intent-based execution, where users specify the desired transaction outcome and third-party fillers or solvers compete to execute the order. Depending on the supported asset, network and available route, users may benefit from broader liquidity access, competitive quotes, gas-abstracted execution and protection against adverse MEV, including front-running and sandwich attacks.
Limit-order functionality powered by 1inch allows users to set a target price and order expiry without continuously monitoring the market. Orders are cryptographically signed and remain offchain until filled. Market swaps and limit orders are available through the same wallet interface, providing a more consistent experience across immediate and target-price execution.
The upgrade also unlocks more flexible execution for eligible tokenized assets referencing stocks, ETFs and other supported RWAs, giving users expanded access to onchain markets and additional trading routes, subject to issuer requirements, user eligibility, network support, market availability and liquidity conditions.
By combining multichain access, broader market coverage and more flexible execution, KuCoin Web3 Wallet continues to evolve as an all-in-one self-custodial platform connecting users to crypto-native and TradFi-linked onchain opportunities.
About KuCoin Web3 Wallet
KuCoin Web3 Wallet is a self-custodial, multichain wallet and onchain access platform built for trading, market discovery and asset management. It brings together cross-chain swaps, wallet-native perpetual trading, supported tokenized real-world assets, Smart Money insights, and DApps within one connected experience. By integrating liquidity, execution and discovery tools directly into the wallet, KuCoin Web3 Wallet helps users move from market insight to onchain action while retaining control of their assets and private keys. With access to over 1,000 DApps and a dedicated airdrop hub featuring trending and newly listed tokens, KuCoin Web3 Wallet provides unified access to crypto-native and TradFi-linked onchain markets.
Learn more: X | Telegram | Instagram
Disclaimer
The information is for corporate PR purposes only and does not constitute endorsement or investment advice.
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kucoin-web3-wallet-advances-onchain-execution-with-expanded-swap-routes-and-limit-orders-302867462.html
2, Sep 2026
VST Tillers Tractors and Union Bank Partner to Make Farm Equipment Finance More Accessible
Partnership to facilitate affordable financing for VST’s range of tractors and farm mechanisation products through its 1,000+ dealer network across India
Bengaluru, India | Sept 02: VST Tillers Tractors Limited (VTTL), a leading manufacturer of compact tractors and farm mechanisation solutions, has signed a Memorandum of Understanding (MoU) with Union Bank of India to facilitate retail finance for customers purchasing VST’s range of agricultural and farm equipment.
Under the MoU, Union Bank of India will facilitate retail loan facilities for customers purchasing VST Tillers Tractors’ products, including Tractors, Power Tillers, Power Reapers and Power Weeders. The initiative is aimed at making farm mechanisation more accessible to the farming community by providing affordable and convenient financing options.
The financing facility will be available through VST’s extensive network of over 1,000 dealers across India, enabling farmers and customers to access financing closer to their communities and support the purchase of suitable farm equipment.
Dr. HT Vasappa ,GM, Union Bank of India said “We are pleased to partner with VST Tillers Tractors to facilitate convenient and affordable retail finance for farmers and customers looking to invest in agricultural mechanisation. Through this collaboration, we aim to strengthen access to credit and enable farmers to acquire modern farm equipment through VST’s wide dealer network. This partnership reflects Union Bank of India’s commitment to supporting the agricultural sector and contributing to the financial empowerment of the farming community.”
On VST’s partnership with Union Bank of India, Antony Cherukara, CEO, VST Tillers Tractors Ltd said “at VST Tillers Tractors, we believe that access to affordable financing is an important enabler of farm mechanisation. Our partnership with Union Bank of India will make it easier for farmers to access financing for our range of tractors and farm equipment through our extensive dealer network. This initiative reinforces our promise to empowering the farming community with accessible, efficient and technology-driven mechanisation solutions that can support greater productivity and sustainable growth.”
The partnership is expected to strengthen access to mechanisation solutions for farmers, helping them adopt modern agricultural equipment while managing their investment through accessible financing options.
2, Sep 2026
Mr Sohil Bhargava appointed Director – Operations at THE Park Hotels’ upcoming hotel
Commenting on his appointment, Mr Sohil Bhargava, Director – Operations for the upcoming hotel, added, “It is an honour to be part of THE Park Hotels and take on the responsibility of leading operational preparations for the upcoming hotel. I look forward to working with the team closely to create differentiated experiences, deliver excellence and bring the Anything But Ordinary™ spirit to a new market.”
2, Sep 2026
BTL Establishes New Laser Division and Introduces EXOLASE ONE® – The World’s First Fused Erbium Laser
Proprietary technology fuses multiple wavelengths into a single beam to set a new standard of care in laser facial rejuvenation.
PRAGUE, Sept. 2, 2026 /PRNewswire/ — BTL, a global leader in advanced energy-based medical and aesthetic technologies, today announced a major milestone in its corporate history: the official establishment of its dedicated laser division and the upcoming launch of its flagship laser system, EXOLASE ONE®.
EXOLASE ONE® is a major leap in the aesthetic industry as the first-ever application of fused erbium laser technology in medical practice. The system fuses multiple erbium laser wavelengths into a single beam of light, treating the exact same spot simultaneously. This creates a completely new form of laser-tissue interaction that overcomes the traditional limitations of existing facial rejuvenation lasers regarding clinical efficacy, speed of treatment, and patient comfort.
“The technology covers what normally requires multiple ablative and non-ablative systems, transforming it into a remarkably simple procedure that treats the entire face in under 10 minutes while delivering superior results for our patients,” said Dr. Reha Yavuzer, one of the first clinical investigators for the platform.
EXOLASE ONE® is the latest high-tech breakthrough originating from BTL’s extensive R&D infrastructure, which has powered many of the company’s industry-defining innovations.
“This is a historic moment for BTL. From the beginning, we knew that only a genuinely disruptive technology would allow us to build a true laser powerhouse,” said Tomas Schwarz, CEO of BTL Group of Companies. “Based on feedback from pioneering clinical centers worldwide, EXOLASE ONE® represents exactly this kind of breakthrough.“
Following an early-access program for selected key opinion leaders, EXOLASE ONE® will move to a broader global launch in 2027, initially focused on aesthetic medicine and dermatology. The new laser division becomes BTL’s sixth core division, complementing its existing operations in aesthetics, mental wellness, rehabilitation, cardiology, and robotics.
About BTL
Founded in 1993, BTL has grown to become one of the world’s major medical and aesthetic equipment manufacturers. With over 5,000 employees located in more than 90 countries, BTL has revolutionized the industry by offering the most advanced non-invasive solutions for body shaping, skin tightening, facial rejuvenation, mental health, rehabilitation and cardiology. BTL’s pioneering brands include EMSCULPT NEO®, EMFACE®, EMSELLA®, EXOMIND® and many others. For more information about BTL and its portfolio of medical innovations, please visit www.btlaesthetics.com.
Press team: media@btlnet.com
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/btl-establishes-new-laser-division-and-introduces-exolase-one–the-worlds-first-fused-erbium-laser-302867440.html
2, Sep 2026
HSBC Mutual Fund’s RedHex Hybrid Long-Short Fund crosses ₹1,000 crore AUM
Strong investor response highlights growing demand for differentiated investment solutions under the SIF framework
MUMBAI, India, Sept. 2, 2026 /PRNewswire/ — HSBC Mutual Fund’s RedHex Hybrid Long-Short Fund, a Specialised Investment Fund (SIF) strategy, has crossed the ₹1,000 crore AUM*, within just 2 months of its listing.
The fund has garnered strong investor interest, with around 1,950 unique folios* participating in the strategy, reflecting growing demand for differentiated investment solutions that offer greater portfolio flexibility and diversification. Launched in June 2026, RedHex combines investments across various asset classes, including fixed income, equity arbitrage, REITs and INVITs to pursue risk-adjusted returns across market cycles.
Kailash Kulkarni, CEO, HSBC Mutual Fund, said, “Investor preferences are evolving, with a growing appetite for investment solutions that offer greater flexibility and diversification while retaining the transparency and discipline associated with mutual funds. This achievement of ₹1,000 crore in AUM is a strong reflection of this evolving demand and the growing relevance of the SIF category. We believe solutions such as RedHex can play an important role in addressing the needs of investors seeking differentiated approaches to portfolio construction.”
Shriram Ramanathan, CIO – Fixed Income, HSBC Mutual Fund, said, “RedHex Hybrid Long-Short Fund is built around a disciplined approach to portfolio construction, with a focus on asset allocation, robust credit selection, accrual potential, and prudent risk management, while keeping overall volatility relatively low. Crossing the ₹1,000 crore AUM demonstrates the confidence investors have placed in this differentiated strategy, which combines fixed income with equity arbitrage, REITs and INVITs. Our focus remains on maintaining a measured approach to risk while seeking to generate consistent risk-adjusted outcomes across market cycles.”
The fund’s strategy seeks to deliver strong accrual potential with relatively low volatility through diversified allocation across asset classes. It aims to generate regular income in a tax efficient manner, while limiting sensitivity to market movements, supported by active portfolio management and strategy-level risk controls.
The strong response to RedHex SIF comes amid the evolving SIF landscape in India, with investors increasingly looking for solutions positioned between traditional mutual funds and higher-ticket investment products such as Portfolio Management Services (PMS) and Alternative Investment Funds (AIFs). RedHex SIF has been designed as an intermediate investment solution offering the regulatory transparency of mutual funds along with greater portfolio flexibility.
The fund is benchmarked against the NIFTY 50 Hybrid Composite Debt 50:50 Index.
Knowledge Centre: Videos, Blogs & Insights | RedHex SIF – HSBC Mutual Fund
Past performance may or may not be sustained in future and is not a guarantee of any future returns. Please read Investment Strategy Information Document (ISID) of the Fund for more details.
*AUM & Folio details as on August 25, 2026 or latest available
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/hsbc-mutual-funds-redhex-hybrid-long-short-fund-crosses-1-000-crore-aum-302867418.html
